170 related articles for article (PubMed ID: 33331739)
1. Recent advances in small cell lung cancer: the future is now?
Luciani A; Blasi M; Provenzano L; Zonato S; Ferrari D
Minerva Endocrinol (Torino); 2022 Dec; 47(4):460-474. PubMed ID: 33331739
[TBL] [Abstract][Full Text] [Related]
2. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Remon J; Aldea M; Besse B; Planchard D; Reck M; Giaccone G; Soria JC
Ann Oncol; 2021 Jun; 32(6):698-709. PubMed ID: 33737119
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR; Yang P; Cassivi SD; Schild SE; Adjei AA
Mayo Clin Proc; 2008 May; 83(5):584-94. PubMed ID: 18452692
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Progress in the Immunotherapy of Small Cell Lung Cancer].
Wang W; Zhang J; Li S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):425-433. PubMed ID: 35747922
[TBL] [Abstract][Full Text] [Related]
8. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
9. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
[TBL] [Abstract][Full Text] [Related]
10. Surgery for limited-stage small-cell lung cancer.
Barnes H; See K; Barnett S; Manser R
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011917. PubMed ID: 28429473
[TBL] [Abstract][Full Text] [Related]
11. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
12. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
Amarasena IU; Chatterjee S; Walters JA; Wood-Baker R; Fong KM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006849. PubMed ID: 26233609
[TBL] [Abstract][Full Text] [Related]
13. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
[TBL] [Abstract][Full Text] [Related]
14. [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):572-8. PubMed ID: 24229622
[TBL] [Abstract][Full Text] [Related]
15. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
[TBL] [Abstract][Full Text] [Related]
16. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
17. The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.
Tsiouprou I; Zaharias A; Spyratos D
Can Respir J; 2019; 2019():6860432. PubMed ID: 31781314
[TBL] [Abstract][Full Text] [Related]
18. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
19. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.
Matsubara T; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Seto T; Okamoto T
Thorac Cancer; 2021 Dec; 12(23):3286-3289. PubMed ID: 34689423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
